Arkolith/Insider Trading/NSRX/Form 4

Teleman Dan Benjamin

Chief Executive Officer, DirectorNasus Pharma Ltd (NSRX) · full profile →Form 4 · filed Apr 1, 2026
Net Buying
Open-Market Buys
$31K
Open-Market Sells
$0
Net Open-Market Flow
$31K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2026Buy(P)15K$2.04$31K21K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-26-014503) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML